AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Cancer Education
Explore expert insights on the fundamentals of cancer, including how it develops, key risk factors, prevention strategies, and treatment options. This section also highlights cancer awareness months and related observance days and weeks. Commentaries from our network of oncology professionals shed light on critical issues that require greater attention across the cancer care and research continuum.
Clinical Review of Cellular Therapies for Multiple Myeloma Part II: Toxicities of CAR-T for the Community and Rural Oncologist
By Adeel M Khan MD MPH MS; Aimaz Afrough, MD; Samer Al Hadidi, MD, MS; Sean Taasan, MD; Larry D Anderson Jr, MD, PhD
While ide-cel and cilta-cel are generally considered safe and have remarkable therapeutic impact for relapsed/refractory myeloma, both agents carry a broad and clinically significant toxicity burden that practitioners must recognize and actively surveil.
Clinical Review of Cellular Therapies for Multiple Myeloma Part II: Toxicities of CAR-T for the Community and Rural Oncologist
By Adeel M Khan MD MPH MS; Aimaz Afrough, MD; Samer Al Hadidi, MD, MS; Sean Taasan, MD; Larry D Anderson Jr, MD, PhD
While ide-cel and cilta-cel are generally considered safe and have remarkable therapeutic impact for relapsed/refractory myeloma, both agents carry a broad and clinically significant toxicity burden that practitioners must recognize and actively surveil.
Clinical Review of Cellular Therapies for Multiple Myeloma Part II: Toxicities of CAR-T for the Community and Rural Oncologist
By Adeel M Khan MD MPH MS; Aimaz Afrough, MD; Samer Al Hadidi, MD, MS; Sean Taasan, MD; Larry D Anderson Jr, MD, PhD
While ide-cel and cilta-cel are generally considered safe and have remarkable therapeutic impact for relapsed/refractory myeloma, both agents carry a broad and clinically significant toxicity burden that practitioners must recognize and actively surveil.
Clinical Review of Cellular Therapies for Multiple Myeloma Part I: A Primer on CAR-T for the Community and Rural Oncologist
By Adeel M Khan MD MPH MS; Aimaz Afrough, MD; Samer Al Hadidi, MD, MS; Sean Taasan, MD; Larry D Anderson Jr, MD, PhD
Ide-cel was the first anti-BCMA CAR-T product approved by the FDA in March 2021, employing a single anti-BCMA single-chain variable fragment.
Clinical Review of Cellular Therapies for Multiple Myeloma Part I: A Primer on CAR-T for the Community and Rural Oncologist
By Adeel M Khan MD MPH MS; Aimaz Afrough, MD; Samer Al Hadidi, MD, MS; Sean Taasan, MD; Larry D Anderson Jr, MD, PhD
Ide-cel was the first anti-BCMA CAR-T product approved by the FDA in March 2021, employing a single anti-BCMA single-chain variable fragment.
Clinical Review of Cellular Therapies for Multiple Myeloma Part I: A Primer on CAR-T for the Community and Rural Oncologist
By Adeel M Khan MD MPH MS; Aimaz Afrough, MD; Samer Al Hadidi, MD, MS; Sean Taasan, MD; Larry D Anderson Jr, MD, PhD
Ide-cel was the first anti-BCMA CAR-T product approved by the FDA in March 2021, employing a single anti-BCMA single-chain variable fragment.
Daraxonrasib: The New Pancreatic Cancer Drug Patients Can Access Now through Clinical Trial Showing Promising Results
By Krutika Gohil, MD
Results of the RASolute 302 clinical trial show Daraxonrasib nearly doubles survival with fewer side effects compared to chemotherapy for pancreatic cancer patients.
Daraxonrasib: The New Pancreatic Cancer Drug Patients Can Access Now through Clinical Trial Showing Promising Results
By Krutika Gohil, MD
Results of the RASolute 302 clinical trial show Daraxonrasib nearly doubles survival with fewer side effects compared to chemotherapy for pancreatic cancer patients.
Daraxonrasib: The New Pancreatic Cancer Drug Patients Can Access Now through Clinical Trial Showing Promising Results
By Krutika Gohil, MD
Results of the RASolute 302 clinical trial show Daraxonrasib nearly doubles survival with fewer side effects compared to chemotherapy for pancreatic cancer patients.
Multiple Myeloma and Plasma Cell Disorders in 2026: Bispecifics Move Earlier, MRD Guides Duration, and Amyloidosis Finally Has a Target
By Laahn Foster, MD
The data presented at ASCO 2026 provide more clarity on where bispecifics fit in the treatment sequence, how long to use them, and whether they can be used as an earlier intervention.
Multiple Myeloma and Plasma Cell Disorders in 2026: Bispecifics Move Earlier, MRD Guides Duration, and Amyloidosis Finally Has a Target
By Laahn Foster, MD
The data presented at ASCO 2026 provide more clarity on where bispecifics fit in the treatment sequence, how long to use them, and whether they can be used as an earlier intervention.
Multiple Myeloma and Plasma Cell Disorders in 2026: Bispecifics Move Earlier, MRD Guides Duration, and Amyloidosis Finally Has a Target
By Laahn Foster, MD
The data presented at ASCO 2026 provide more clarity on where bispecifics fit in the treatment sequence, how long to use them, and whether they can be used as an earlier intervention.
Next-Generation KRAS Inhibitors in NSCLC: A Pipeline So Active It's Hard to Keep Up
By Robert Chun-Hao Hsu, MD
KRAS was considered undruggable for decades. The protein's smooth, shallow surface offered no obvious pocket for small molecule binding. Its extremely high affinity for GTP/GDP made competitive inhibition impractical.
Next-Generation KRAS Inhibitors in NSCLC: A Pipeline So Active It's Hard to Keep Up
By Robert Chun-Hao Hsu, MD
KRAS was considered undruggable for decades. The protein's smooth, shallow surface offered no obvious pocket for small molecule binding. Its extremely high affinity for GTP/GDP made competitive inhibition impractical.
Next-Generation KRAS Inhibitors in NSCLC: A Pipeline So Active It's Hard to Keep Up
By Robert Chun-Hao Hsu, MD
KRAS was considered undruggable for decades. The protein's smooth, shallow surface offered no obvious pocket for small molecule binding. Its extremely high affinity for GTP/GDP made competitive inhibition impractical.
Small Cell Lung Cancer in 2026: A Field That Has Finally Started Moving
By Deepti Behl, MD
Platinum-etoposide served as the cornerstone of therapy, producing rapid responses that were often followed by equally rapid relapses, and few effective subsequent options.
Small Cell Lung Cancer in 2026: A Field That Has Finally Started Moving
By Deepti Behl, MD
Platinum-etoposide served as the cornerstone of therapy, producing rapid responses that were often followed by equally rapid relapses, and few effective subsequent options.
Small Cell Lung Cancer in 2026: A Field That Has Finally Started Moving
By Deepti Behl, MD
Platinum-etoposide served as the cornerstone of therapy, producing rapid responses that were often followed by equally rapid relapses, and few effective subsequent options.
Peripheral T-Cell Lymphoma in 2026: Reclassification, BV-CHP as Standard, and a Pipeline Finally Targeting Disease Biology
By Ranjit Nair, MD
Peripheral T-cell lymphomas are among the most challenging malignancies in hematologic oncology.
Peripheral T-Cell Lymphoma in 2026: Reclassification, BV-CHP as Standard, and a Pipeline Finally Targeting Disease Biology
By Ranjit Nair, MD
Peripheral T-cell lymphomas are among the most challenging malignancies in hematologic oncology.
Peripheral T-Cell Lymphoma in 2026: Reclassification, BV-CHP as Standard, and a Pipeline Finally Targeting Disease Biology
By Ranjit Nair, MD
Peripheral T-cell lymphomas are among the most challenging malignancies in hematologic oncology.
Bispecific Antibodies and Fixed-Duration CLL Therapy: The Lymphoma and CLL Landscape in 2026
By Jennifer Huang, PhD, MD
The 2026 lymphoma and CLL landscape is defined by maturing long-term data, the shift of bispecific antibodies into earlier treatment lines, and the emergence of all-oral, fixed-duration regimens.
Bispecific Antibodies and Fixed-Duration CLL Therapy: The Lymphoma and CLL Landscape in 2026
By Jennifer Huang, PhD, MD
The 2026 lymphoma and CLL landscape is defined by maturing long-term data, the shift of bispecific antibodies into earlier treatment lines, and the emergence of all-oral, fixed-duration regimens.
Bispecific Antibodies and Fixed-Duration CLL Therapy: The Lymphoma and CLL Landscape in 2026
By Jennifer Huang, PhD, MD
The 2026 lymphoma and CLL landscape is defined by maturing long-term data, the shift of bispecific antibodies into earlier treatment lines, and the emergence of all-oral, fixed-duration regimens.
Early-Stage Lung Cancer in 2026: Why Detection Still Changes Everything
By Thomas Templin, MD MBA
Lung cancer remains the world’s leading cause of cancer death. Reducing tobacco use has helped, but it has not solved the problem.
Early-Stage Lung Cancer in 2026: Why Detection Still Changes Everything
By Thomas Templin, MD MBA
Lung cancer remains the world’s leading cause of cancer death. Reducing tobacco use has helped, but it has not solved the problem.
Early-Stage Lung Cancer in 2026: Why Detection Still Changes Everything
By Thomas Templin, MD MBA
Lung cancer remains the world’s leading cause of cancer death. Reducing tobacco use has helped, but it has not solved the problem.
Soy and Breast Cancer: Is It Safe to Eat Tofu?
By Ariana Sutherland
Tofu has a reputation for raising estrogen levels—but the science tells a different story. An oncologist explains why soy's isoflavones may actually behave more like estrogen blockers than estrogen itself.
Soy and Breast Cancer: Is It Safe to Eat Tofu?
By Ariana Sutherland
Tofu has a reputation for raising estrogen levels—but the science tells a different story. An oncologist explains why soy's isoflavones may actually behave more like estrogen blockers than estrogen itself.
Soy and Breast Cancer: Is It Safe to Eat Tofu?
By Ariana Sutherland
Tofu has a reputation for raising estrogen levels—but the science tells a different story. An oncologist explains why soy's isoflavones may actually behave more like estrogen blockers than estrogen itself.